Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.57 CAD | +6.80% | -2.48% | -53.13% |
May. 14 | Transcript : Aptose Biosciences Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.13% | 17.5M | |
+68.63% | 62.86B | |
-1.08% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.14% | 26.46B | |
-22.09% | 18.9B | |
+4.28% | 12.67B | |
+24.24% | 12.27B | |
+28.22% | 12.07B |
- Stock Market
- Equities
- APS Stock
- News Aptose Biosciences Inc.
- Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations with Excellent Safety Profile"